Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(velaglucerase alfa)
77 results
  • Budget Impact Analysis of Eliglustat for the Treatment of Gaucher Disease Type 1 in the United States. [Journal Article]
    J Manag Care Spec Pharm 2018; 24(10):1002-1008Nalysnyk L, Sugarman R, … Ward A
  • CONCLUSIONS: Based on these analyses, increased use of eliglustat resulted in meaningful cost savings to a payer's overall budget. Cost savings are highest among patients switching from ERT administered in a hospital outpatient setting. The results suggest that cost savings are also likely achievable from initiating patients on oral eliglustat instead of infusion-based therapy from the outset of treatment.
  • Drugs and Lactation Database (LactMed): Velaglucerase alfa [BOOK]
    National Library of Medicine (US): Bethesda (MD)BOOK
  • No information is available on the clinical use of velaglucerase during breastfeeding. Velalglucerase is a synthetic form of beta-glucocerebrosidase, which is a normal component of human milk. Studies with other forms of the enzyme have found very low levels of the enzyme in breastmilk. Absorption by the infant is unlikely because it is probably destroyed in the infant's gastrointestinal tract.[1…
  • Spotlight on taliglucerase alfa in the treatment of pediatric patients with type 1 Gaucher disease. [Review]
    Pediatric Health Med Ther 2017; 8:73-81Gupta P, Pastores GM
  • Gaucher disease (GD) is a heritable storage disorder caused by functional defects of the lysosomal acid β-glucosidase and the accumulation of glucosylceramide within macrophages, resulting in multiple organ dysfunction. There are three commercially available enzyme replacement therapy (ERT) products for the treatment of GD type 1 (GD1): imiglucerase, velaglucerase alfa, and taliglucerase alfa. Im…
  • Lysosomal storage diseases. [Review]
    Transl Sci Rare Dis 2017; 2(1-2):1-71Ferreira CR, Gahl WA
  • Lysosomes are cytoplasmic organelles that contain a variety of different hydrolases. A genetic deficiency in the enzymatic activity of one of these hydrolases will lead to the accumulation of the material meant for lysosomal degradation. Examples include glycogen in the case of Pompe disease, glycosaminoglycans in the case of the mucopolysaccharidoses, glycoproteins in the cases of the oligosacch…
New Search Next